Radioiodine therapy in benign thyroid diseases: effects, side effects, and factors affecting therapeutic outcome

SJ Bonnema, L Hegedüs - Endocrine reviews, 2012 - academic.oup.com
Radioiodine (131I) therapy of benign thyroid diseases was introduced 70 yr ago, and the
patients treated since then are probably numbered in the millions. Fifty to 90% of …

The role of radioiodine therapy in benign nodular goitre

SJ Bonnema, S Fast, L Hegedüs - Best Practice & Research Clinical …, 2014 - Elsevier
For treatment of benign nodular goitre the choice usually stands between surgery and 131 I
therapy. 131 I therapy, used for 30 years for this condition, leads to a goitre volume reduction …

Prestimulation with recombinant human thyrotropin (rhTSH) improves the long-term outcome of radioiodine therapy for multinodular nontoxic goiter

S Fast, VE Nielsen, P Grupe… - The Journal of …, 2012 - academic.oup.com
Objective: The objective of the study was to evaluate the long-term outcome of recombinant
human TSH (rhTSH)-augmented radioiodine (131I) therapy for benign multinodular nontoxic …

Modified-Release Recombinant Human TSH (MRrhTSH) Augments the Effect of 131I Therapy in Benign Multinodular Goiter: Results from a Multicenter International …

H Graf, S Fast, F Pacini, A Pinchera… - The Journal of …, 2011 - academic.oup.com
Background: Recombinant human TSH (rhTSH) can be used to enhance 131I therapy for
shrinkage of multinodular goiter (MG). Objective, Design, and Setting: The objective of the …

Long-term efficacy of modified-release recombinant human thyrotropin augmented radioiodine therapy for benign multinodular goiter: results from a multicenter …

S Fast, L Hegedüs, F Pacini, A Pinchera, AM Leung… - Thyroid, 2014 - liebertpub.com
Background: Enhanced reduction of multinodular goiter (MNG) can be achieved by
stimulation with recombinant human thyrotropin (rhTSH) before radioiodine (131I) therapy …

Non-surgical approach to the benign nodular goiter: new opportunities by recombinant human TSH-stimulated 131I-therapy

SJ Bonnema, S Fast, L Hegedüs - Endocrine, 2011 - Springer
The optimal treatment strategy in a goiter patient depends—among other factors—on goiter
size, the degree of cosmetic or compressive symptoms, the age of the patient, the impact on …

Recombinant human thyrotropin before 131I therapy in patients with nodular goitre: a meta‐analysis of randomized controlled trials

YY Lee, KW Tam, YM Lin, WJ Leu… - Clinical …, 2015 - Wiley Online Library
Background Recombinant human thyrotropin (rhTSH) can be used to enhance radioiodine
therapy for shrinking multinodular goitre. The aim of this meta‐analysis was to compare the …

Therapy of Endocrine Disease: Recombinant human TSH and radioactive iodine therapy in the management of benign multinodular goiter

H Graf - European Journal of Endocrinology, 2015 - academic.oup.com
Multinodular goiter (MNG) is a very common thyroid disorder determined by diverse
goitrogenic factors, the most important one being iodine deficiency. The clinical presentation …

Long-term outcome after radioiodine therapy with adjuvant rhTSH treatment: comparison between patients with non-toxic and pre-toxic large multinodular goitre

M Giusti, V Caorsi, L Mortara, M Caputo, E Monti… - Endocrine, 2014 - Springer
In multinodular goitre (MNG), low radioiodine (RAI) activity after recombinant human (rh)
TSH is able to reduce thyroid volume (TV) and improve symptoms. Our aim was to evaluate …

Radioiodine therapy of benign non-toxic goitre. Potential role of recombinant human TSH

S Fast, SJ Bonnema, L Hegedüs - Annales D'endocrinologie, 2011 - Elsevier
This review provides an update on recombinant human TSH (rh-TSH) augmented
radioiodine (131 I) therapy and outlines its potential role in the treatment of symptomatic …